Actively Recruiting

Phase Not Applicable
Age: 18Years - 75Years
All Genders
NCT06128252

Clinical Study of Taurine Combined With Neoadjuvant Chemo-Immunotherapy for Treatment of Locally Advanced Gastric Cancer

Led by Tang-Du Hospital · Updated on 2025-01-07

96

Participants Needed

6

Research Sites

95 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This project aims to evaluate the efficacy and safety of oral taurine supplementation combined with PD-1 inhibitor (serplulimab) and chemotherapy in inducing systemic CD8+ T cell responses and achieving improved gastric cancer patient outcomes than with serplulimab and chemotherapy alone.

CONDITIONS

Official Title

Clinical Study of Taurine Combined With Neoadjuvant Chemo-Immunotherapy for Treatment of Locally Advanced Gastric Cancer

Who Can Participate

Age: 18Years - 75Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 18 to 75 years, any gender
  • Pathologically confirmed gastric or gastroesophageal junction adenocarcinoma with clinical TNM stage II or III, T3, N 650, M=0
  • Expected survival of at least 3 months
  • Tumor specimens PD-L1 positive with combined positive score (CPS) 61
  • Presence of measurable lesions suitable for radical R0 resection after doctor evaluation
  • Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1
  • Provided written informed consent after understanding study purpose and procedures
Not Eligible

You will not qualify if you...

  • Use of taurine agents within 1 month before starting study treatment or during the study
  • Positive for HER-2
  • Presence of gastrointestinal obstruction, active gastrointestinal bleeding, perforation, or difficulty swallowing
  • Severe diseases affecting heart, lung, liver, kidney, endocrine, hematopoietic, or psychiatric systems making participation unsuitable
  • HIV infection, AIDS, autoimmune diseases, or current use of immunosuppressants
  • Any other severe acute or chronic diseases or conditions judged by investigators to increase risk or be unsuitable for the study

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 6 locations

1

Xi-jing Hospital

Xi'an, Shaanxi, China, 710032

Actively Recruiting

2

Tang-Du Hospital

Xi'an, Shaanxi, China, 710038

Actively Recruiting

3

Shaanxi Provincial People's Hospital

Xi'an, Shaanxi, China, 710068

Actively Recruiting

4

Xi 'an International Medical Center Hospital

Xi'an, Shaanxi, China, 710100

Actively Recruiting

5

The Second Affilated Hospital Of Xi'an Jiaotong University (Xibei Hospital)

Xi'an, Shaanxi, China

Actively Recruiting

6

Xi'an NO.3 hospital

Xi'an, Shaanxi, China

Actively Recruiting

Loading map...

Research Team

X

Xiaodi Zhao, MD, PhD

CONTACT

X

Xin Wang, MD, PhD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Clinical Study of Taurine Combined With Neoadjuvant Chemo-Immunotherapy for Treatment of Locally Advanced Gastric Cancer | DecenTrialz